Susan Reutzel-Edens | Academic Influence

Susan Reutzel-Edens's AcademicInfluence.com Rankings

Susan Reutzel-Edens

Chemistry

#5853

World Rank

#7105

Historical Rank

chemistry Degrees

Download Badge

Chemistry

Susan Reutzel-Edens's Degrees

PhD Chemistry University of California, Berkeley
Bachelors Chemistry University of California, Berkeley

Why Is Susan Reutzel-Edens Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Susan Reutzel-Edens is an American chemist who is the Head of Science at the Cambridge Crystallographic Data Centre. Her work considers solid state chemistry and pharmaceuticals. She is interested in crystal structure predictions. She serves on the editorial boards of CrystEngComm and Crystal Growth & Design.

(See a Problem?)

Susan Reutzel-Edens's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Facts and fictions about polymorphism. (2015) (325)
Characterization of the solid state: quantitative issues. (2001) (192)
Characterization of the "hygroscopic" properties of active pharmaceutical ingredients. (2008) (145)
Anhydrates and Hydrates of Olanzapine: Crystallization, Solid-State Characterization, and Structural Relationships (2003) (121)
Exploring the Experimental and Computed Crystal Energy Landscape of Olanzapine (2013) (114)
Assessment of the amorphous "solubility" of a group of diverse drugs using new experimental and theoretical approaches. (2015) (110)
Can computed crystal energy landscapes help understand pharmaceutical solids? (2016) (110)
Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. (2009) (95)
The potential of computed crystal energy landscapes to aid solid-form development. (2016) (79)
A Prolific Solvate Former, Galunisertib, Under the Pressure of Crystal Structure Prediction, Produces Ten Diverse Polymorphs. (2019) (73)
Contrasting Polymorphism of Related Small Molecule Drugs Correlated and Guided by the Computed Crystal Energy Landscape (2014) (67)
Coamorphous Active Pharmaceutical Ingredient-Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability. (2018) (63)
Supersaturation Potential of Salt, Co-Crystal, and Amorphous Forms of a Model Weak Base (2016) (60)
Navigating the Waters of Unconventional Crystalline Hydrates (2015) (57)
A molecular picture of the problems in ensuring structural purity of tazofelone (2014) (35)
Crystal structure prediction is changing from basic science to applied technology. (2018) (34)
Evaluating Competing Intermolecular Interactions through Molecular Electrostatic Potentials and Hydrogen-Bond Propensities (2018) (32)
Direct observation of templated two-step nucleation mechanism during olanzapine hydrate formation (2017) (31)
Insight into Amorphous Solid Dispersion Performance by Coupled Dissolution and Membrane Mass Transfer Measurements. (2018) (30)
Crystal forms of LY334370 HCl: isolation, solid-state characterization, and physicochemical properties. (2003) (29)
Physical Characterization of Hygroscopicity in Pharmaceutical Solids (2006) (29)
Absorptive Dissolution Testing of Supersaturating Systems: Impact of Absorptive Sink Conditions on Solution Phase Behavior and Mass Transport. (2017) (29)
Modeling Olanzapine Solution Growth Morphologies (2017) (29)
Molecular basis for the stability relationships between homochiral and racemic crystals of tazofelone: a spectroscopic, crystallographic, and thermodynamic investigation (2000) (26)
Accuracy and reproducibility in crystal structure prediction: the curious case of ROY (2019) (26)
Unraveling Complexity in the Solid Form Screening of a Pharmaceutical Salt: Why so Many Forms? Why so Few? (2017) (23)
Achieving polymorph selectivity in the crystallization of pharmaceutical solids: basic considerations and recent advances. (2006) (21)
Inconvenient Truths about Solid Form Landscapes Revealed in the Polymorphs and Hydrates of Gandotinib (2019) (18)
Absorptive dissolution testing: An improved approach to study the impact of residual crystallinity on the performance of amorphous formulations. (2019) (13)
A random forest model for predicting crystal packing of olanzapine solvates (2018) (13)
Diastereomeric Salt Resolution Based Synthesis of LY503430, an AMPA (α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid) Potentiator (2005) (12)
Development of a Practical Synthesis of an Aminoindanol-Derived M1 Agonist† (2009) (11)
Influence of Drug-Silica Electrostatic Interactions on Drug Release from Mesoporous Silica-Based Oral Delivery Systems. (2020) (10)
Interplay of Adsorption, Supersaturation and the Presence of an Absorptive Sink on Drug Release from Mesoporous Silica-Based Formulations (2020) (8)
Hygroscopicity and Hydrates in Pharmaceutical Solids (2018) (6)
Chapter 10:Analytical Techniques and Strategies for Salt/Co-crystal Characterization (2011) (5)
NMR Crystallography and the Elucidation of Structure-Property Relationships in Crystalline Solids (2008) (4)
The unexpected discovery of the ninth polymorph of tolfenamic acid (2021) (4)
Powder diffraction and pharmaceuticals (2019) (4)
Crystal forms in pharmaceutical applications: olanzapine, a gift to crystal chemistry that keeps on giving (2020) (4)
Applications of crystal structure prediction - organic molecular structures: general discussion. (2018) (3)
CRYSTALLIZATION | Basic Principles (2003) (3)
Structure searching methods: general discussion. (2018) (2)
INTERNATIONAL SCHOOL OF CRYSTALLOGRAPHY 39th Course: ENGINEERING OF CRYSTALLINE MATERIALS PROPERTIES: STATE-OF-THE-ART IN MODELLING, DESIGN, APPLICATIONS (2007) (1)
Diabat method for polymorph free energies: Extension to molecular crystals. (2020) (1)
Symmetry in the making (2020) (1)
Can Computed Crystal Energy Landscapes Help Understand Pharmaceutical Solids (2016) (0)
Monochlorhydrate de 3-(1-methyl-1h-indol-3-yl)-4-[[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole-2,5-dione cristallin (2002) (0)
Phosphate (3-cyano-1H-indol-7-yl) - [4- (4-fluorophenethyl) piperazin-1-yl] methanone (2007) (0)
Computed crystal energy landscapes: a first step towards digital drug product design? (2016) (0)
Experimental and computational approaches towards solid-form screening of pharmaceuticals (2013) (0)
2,5-diona-3- (1-methyl-1h-indol-3-il) -4-1 (piridin-2-ilmetil) piperidin-4-il-1h-indol-3-il-1h crystal monoclorhydrate -pirrol. (2003) (0)
Crystallography (1973) (0)
Kristalline (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanon-phosphat (2007) (0)
Atomic force microscopy studies on two-step nucleation and epitaxial growth (2015) (0)
Facts and Fictions About Polymorphism (2016) (0)
New crystalline form of N- (4- (2- (2-amino-4,7-dihydro-3h-pyrrolo 4.oxo-(2,3-d) pyrimidin-5-yl) ethyl (benzoyl) -L-glutamic acid and preparation process. (2001) (0)
Controlling crystal polymorphism: from stability prediction to crystallization process design (2005) (0)
Physical and Chemical Aspects of Pharmaceutical Solids: Fundamentals of Polymorphs, Hydrates and Solvates (2007) (0)
Crystal Morphology Modeling of Solvates and Hydrates of Organic Molecular Crystals: Olanzapine Solvate and Dihydrate (2021) (0)

This paper list is powered by the following services:

Other Resources About Susan Reutzel-Edens

en.wikipedia.org

What Schools Are Affiliated With Susan Reutzel-Edens?

Susan Reutzel-Edens is affiliated with the following schools:

University of California, Berkeley